Benzinga··Business WireSavara Clears FDA Hurdle for MOLBREEVI as Drug Advances Toward Autoimmune PAP Approval
Savara receives FDA Day 74 Letter for MOLBREEVI with no advisory committee meeting planned. PDUFA target date set for August 2026.
SVRAFDA approvalMOLBREEVI